Psoriasis is a chronic-inflammatory skin disease. In case of moderate and severe psoriasis (approximately 20-30 % of all patients), systemic treatment is necessary. Recent findings regarding the pathomechanism of psoriasis led to the development of targeting molecules, so-called biologics. These biotechnical products are able to selectively block mediators that are relevant for inflammation or to block the interaction between cells, imitating or inhibiting natural proteins.
|Translated title of the contribution
|Treatment of psoriasis with biologics
|Number of pages
|Published - 02.2007
Research Areas and Centers
- Academic Focus: Center for Infection and Inflammation Research (ZIEL)